Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GENFIT S.A.

< Previous 1 2 Next >
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
From GENFIT S.A.
Via GlobeNewswire
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
From GENFIT S.A.
Via GlobeNewswire
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports First Quarter 2025 Financial Information
From GENFIT S.A.
Via GlobeNewswire
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
From GENFIT S.A.
Via GlobeNewswire
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
From GENFIT S.A.
Via GlobeNewswire
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
From GENFIT S.A.
Via GlobeNewswire
GENFIT to Present Latest ACLF Research at EASL Congress 2025
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
From GENFIT S.A.
Via GlobeNewswire
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
From GENFIT S.A.
Via GlobeNewswire
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Revenues and Cash Position as of December 31, 2024
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
From GENFIT S.A.
Via GlobeNewswire
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces 2025 Financial Calendar
From GENFIT S.A.
Via GlobeNewswire
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports Third Quarter 2024 Financial Information
From GENFIT S.A.
Via GlobeNewswire
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
From GENFIT S.A.
Via GlobeNewswire
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
From GENFIT S.A.
Via GlobeNewswire
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
From GENFIT S.A.
Via GlobeNewswire
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
From GENFIT S.A.
Via GlobeNewswire
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
From GENFIT S.A.
Via GlobeNewswire
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
From GENFIT S.A.
Via GlobeNewswire
GENFIT Reports First Quarter 2024 Financial Information
From GENFIT S.A.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.